000			01929 a2200517 4500
005			20250516074807.0
264		0	_c20120522
008			201205s 0 0 eng d
022			_a1881-7122
024	7		_a10.1538/expanim.61.49 _2doi
040			_aNLM _beng _cNLM
100	1		_aFujita, Akiko
245	0	0	_aA novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment. _h[electronic resource]
260			_bExperimental animals _c2012
300			_a49-57 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_a8-Hydroxy-2'-Deoxyguanosine
650	0	4	_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use
650	0	4	_aAnimals
650	0	4	_aBenzimidazoles _xtherapeutic use
650	0	4	_aBiphenyl Compounds _xtherapeutic use
650	0	4	_aDeoxyguanosine _xanalogs & derivatives
650	0	4	_aDiabetes Mellitus, Experimental _xgenetics
650	0	4	_aDiabetes Mellitus, Type 2 _xphysiopathology
650	0	4	_aDiabetic Nephropathies _xdrug therapy
650	0	4	_aDisease Models, Animal
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aHumans
650	0	4	_aKidney _xpathology
650	0	4	_aMaf Transcription Factors, Large _xgenetics
650	0	4	_aMafK Transcription Factor _xgenetics
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Transgenic
650	0	4	_aNephrectomy
650	0	4	_aTetrazoles _xtherapeutic use
700	1		_aYoh, Keigyou
700	1		_aShimohata, Homare
700	1		_aMorito, Naoki
700	1		_aOjima, Masami
700	1		_aOkamura, Midori
700	1		_aTakahashi, Satoru
700	1		_aYamagata, Kunihiro
773	0		_tExperimental animals _gvol. 61 _gno. 1 _gp. 49-57
856	4	0	_uhttps://doi.org/10.1538/expanim.61.49 _zAvailable from publisher's website
999			_c21506813 _d21506813